Biotech Values

[DewDiligence]

…investors who have committed their emotions to the stock in question always begin speaking of new paradigms and how it will be different this time. It seldom is. Today's trading is at least a strong suggestion that it won't be this time, either. The months immediately after approval are the time to be most cautious about the immediate future.

What you’re missing is that MNTA’s approval is for a generic drug that’s fully substitutable for a blockbuster brand. Its sales are assured as long as NVS can make enough of it to meet the demand, and they can.